Spherix Incorporated
SPEX – an innovator in biotechnology for therapy in diabetes,
metabolic syndrome and atherosclerosis, and provider of technical and
regulatory consulting services to food, supplement, biotechnology and
pharmaceutical companies – today announced that it has filed a Certificate of
Amendment to its Certificate of Incorporation, as amended, to effect a
1-for-20 reverse stock split of its common stock that will become effective at
the end of business today. The reverse stock split-adjusted shares of the
Company's common stock will begin trading at the start of NASDAQ trading on
September 24, 2012. The Company's shares will continue to trade on The NASDAQ
Capital Market under the symbol "SPEX", with the fifth character "D" added to
the end of the trading symbol for a period of 20 trading days to indicate the
reverse stock split has occurred. Thereafter, the Company's symbol will revert
to its original symbol "SPEX". A new CUSIP number has been assigned to
Spherix' common stock after the reverse stock split becomes effective.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsStock Split
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in